After a disappointing year for pharmaceutical companies, the Vioxx heat thrown on the FDA, and the withdrawal of Biogen Idec Inc.'s Tysabri, dissecting the drug development model and insinuating pharmacogenomics into it not only is timely, but appropriate.
Savient Pharmaceuticals Inc. has halted its Phase II trial for Prosaptide after an interim analysis indicated the product would not reach its analgesia efficacy endpoint. (BioWorld Today)
RSS